Advertisement

Monitoring of Neurocognitive Function in the Care of Patients with Brain Tumors

  • Kyle R. Noll
  • Mariana E. Bradshaw
  • Michael W. Parsons
  • Erica L. Dawson
  • Jennie Rexer
  • Jeffrey S. WefelEmail author
Neuro-oncology (R Soffietti, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neuro-oncology

Abstract

Purpose of review

A detailed characterization of the nature of neurocognitive impairment in patients with brain tumors is provided, as well as considerations for clinical practice regarding neuropsychological assessment throughout the disease course.

Recent findings

Neurocognitive impairment is common in patients with brain tumors and may result from the tumor itself, as a consequence of treatment, including surgery, chemotherapy, and radiation, or in association with supportive care medications (e.g., anticonvulsant and pain medications). Serial surveillance of neurocognitive functioning in this population can facilitate medical decision-making and inform recommendations to improve patient daily functioning and quality of life.

Summary

Neuropsychological assessment is increasingly recognized as a critical component of the multidisciplinary care of patients with brain tumors and has already had practice-changing effects. Further understanding of genetic risk factors for neurocognitive decline along with the development of novel assessment and intervention strategies may further enhance functioning and general well-being in this patient population.

Keywords

Brain tumor Glioma Neurocognitive function Quality of life 

Notes

Acknowledgments

Jeffrey S. Wefel is supported by the National Institute of Nursing Research of the National Institutes of Health under Award Number R01NR014195. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Compliance with Ethical Standards

Conflict of Interest

Kyle R. Noll, Mariana E. Bradshaw, Erica L. Dawson, and Jennie Rexer each declare no potential conflict of interest. Michael W. Parsons reports consulting fees from Agios Inc. and Monteris Inc. outside the submitted work. Jeffrey S. Wefel reports personal fees from Abbvie, Bayer, Blueprint Medicines, Magnolia Tejas, Novocure, and Vanquish Oncology, and reports grants from Angiochem, Juno, Novocure, and Roche outside the submitted work.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Collins C, Gehrke A, Feuerstein M. Cognitive tasks challenging brain tumor survivors at work. J Occup Environ Med. 2013;55(12):1426–30.  https://doi.org/10.1097/JOM.0b013e3182a64206.CrossRefPubMedGoogle Scholar
  2. 2.
    Chaytor N, Schmitter-Edgecombe M. The ecological validity of neuropsychological tests: a review of the literature on everyday cognitive skills. Neuropsychol Rev. 2003;13(4):181–97.CrossRefGoogle Scholar
  3. 3.
    Noll KR, Bradshaw ME, Weinberg JS, Wefel JS. Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma. Psychooncology. 2017;26(5):617–24.  https://doi.org/10.1002/pon.4046.CrossRefPubMedGoogle Scholar
  4. 4.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.CrossRefGoogle Scholar
  5. 5.
    Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.  https://doi.org/10.1111/j.1532-5415.2005.53221.x.CrossRefPubMedGoogle Scholar
  6. 6.
    Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(19):3557–8.  https://doi.org/10.1200/JCO.2003.07.080JCO.2003.07.080.CrossRefGoogle Scholar
  7. 7.
    Racine CA, Li J, Molinaro AM, Butowski N, Berger MS. Neurocognitive function in newly diagnosed low-grade glioma patients undergoing surgical resection with awake mapping techniques. Neurosurgery. 2015;77(3):371–9: discussion 9.  https://doi.org/10.1227/NEU.0000000000000779.CrossRefPubMedGoogle Scholar
  8. 8.
    Noll KR, Bradshaw ME, Rexer J, Wefel JS. Neuropsychological practice in the oncology setting. Arch Clin Neuropsychol. 2018;33(3):344–53.  https://doi.org/10.1093/arclin/acx131.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Noll KR, Fardell JE. Commentary: “Neuropsychological assessment of individuals with brain tumor: comparison of approaches used in the classification of impairment”. Front Oncol. 2015;5:188.  https://doi.org/10.3389/fonc.2015.00188.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Tucha O, Smely C, Preier M, Lange KW. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery. 2000;47(2):324–33 discussion 33–4.CrossRefGoogle Scholar
  11. 11.
    Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumors. Lancet Neurol. 2004;3(3):159–68.  https://doi.org/10.1016/S1474-4422(04)00680-5.CrossRefPubMedGoogle Scholar
  12. 12.
    Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro-Oncology. 2018;20(suppl_4):iv1–iv86.  https://doi.org/10.1093/neuonc/noy131.CrossRefPubMedGoogle Scholar
  13. 13.
    Meskal I, Gehring K, Rutten GJ, Sitskoorn MM. Cognitive functioning in meningioma patients: a systematic review. J Neuro-Oncol. 2016;128(2):195–205.  https://doi.org/10.1007/s11060-016-2115-z.CrossRefGoogle Scholar
  14. 14.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–20.  https://doi.org/10.1007/s00401-016-1545-1.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Noll KR, Sullaway C, Ziu M, Weinberg JS, Wefel JS. Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection. Neuro-Oncology. 2014;17(4):580–7.  https://doi.org/10.1093/neuonc/nou233.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000;18(3):646–50.  https://doi.org/10.1200/JCO.2000.18.3.646.CrossRefPubMedGoogle Scholar
  17. 17.
    Soffietti R, Ruda R, Mutani R. Management of brain metastases. J Neurol. 2002;249(10):1357–69.  https://doi.org/10.1007/s00415-002-0870-6.CrossRefPubMedGoogle Scholar
  18. 18.
    Witgert ME, Meyers CA. Neurocognitive and quality of life measures in patients with metastatic brain disease. Neurosurg Clin N Am. 2011;22(1):79–85, vii.  https://doi.org/10.1016/j.nec.2010.08.010.CrossRefPubMedGoogle Scholar
  19. 19.
    Vargo MM. Brain tumors and metastases. Phys Med Rehabil Clin N Am. 2017;28(1):115–41.  https://doi.org/10.1016/j.pmr.2016.08.005.CrossRefPubMedGoogle Scholar
  20. 20.
    Wefel JS, Parsons MW, Gondi V, Brown PD. Neurocognitive aspects of brain metastasis. Handb Clin Neurol. 2018;149:155–65.  https://doi.org/10.1016/B978-0-12-811,161-1.00012-8.CrossRefPubMedGoogle Scholar
  21. 21.
    Anderson SW, Damasio H, Tranel D. Neuropsychological impairments associated with lesions caused by tumor or stroke. Arch Neurol. 1990;47(4):397–405.CrossRefGoogle Scholar
  22. 22.••
    Kesler SR, Noll K, Cahill DP, Rao G, Wefel JS. The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. J Neuro-Oncol. 2016.  https://doi.org/10.1007/s11060-016-2328-1 The first demonstration of the impact of tumor genetic variation upon network integrity in patients with malignant astrocytoma. Patients with wild-type tumor demonstrated significantly lower network efficiency in medial frontal, posterior parietal, and subcortical regions.CrossRefGoogle Scholar
  23. 23.
    Noll KR, Sullaway C, Ziu M, Weinberg JS, Wefel JS. Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection. Neuro-Oncology. 2015;17(4):580–7.  https://doi.org/10.1093/neuonc/nou233.CrossRefPubMedGoogle Scholar
  24. 24.
    Wefel JS, Noll KR, Scheurer ME. Neurocognitive functioning and genetic variation in patients with primary brain tumors. Lancet Oncol. 2016;17(3):e97–e108.  https://doi.org/10.1016/S1470-2045(15)00380-0.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Derks J, Reijneveld JC, Douw L. Neural network alterations underlie cognitive deficits in brain tumor patients. Curr Opin Oncol. 2014;26(6):627–33.  https://doi.org/10.1097/CCO.0000000000000126.CrossRefPubMedGoogle Scholar
  26. 26.
    Noll KR, Weinberg JS, Ziu M, Benveniste RJ, Suki D, Wefel JS. Neurocognitive changes associated with surgical resection of left and right temporal lobe glioma. Neurosurgery. 2015;77(5):777–85.  https://doi.org/10.1227/NEU.0000000000000987.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Satoer D, Vork J, Visch-Brink E, Smits M, Dirven C, Vincent A. Cognitive functioning early after surgery of gliomas in eloquent areas. J Neurosurg. 2012;117(5):831–8.  https://doi.org/10.3171/2012.7.JNS12263.CrossRefPubMedGoogle Scholar
  28. 28.
    Tucha O, Smely C, Preier M, Becker G, Paul GM, Lange KW. Preoperative and postoperative cognitive functioning in patients with frontal meningiomas. J Neurosurg. 2003;98(1):21–31.  https://doi.org/10.3171/jns.2003.98.1.0021.CrossRefPubMedGoogle Scholar
  29. 29.
    Hendrix P, Hans E, Griessenauer CJ, Simgen A, Oertel J, Karbach J. Neurocognitive function surrounding the resection of frontal WHO Grade I meningiomas: a prospective matched-control study. World Neurosurg. 2017;98:203–10.  https://doi.org/10.1016/j.wneu.2016.10.095.CrossRefPubMedGoogle Scholar
  30. 30.
    Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, et al. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2013;31(32):4076–84.  https://doi.org/10.1200/JCO.2013.49.6067.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708.  https://doi.org/10.1056/NEJMoa1308573.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 2012;12(3):267–75.  https://doi.org/10.1007/s11910-012-0264-9.CrossRefPubMedGoogle Scholar
  33. 33.
    Prust MJ, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, et al. Standard chemoradiation for glioblastoma results in progressive brain volume loss. Neurology. 2015;85(8):683–91.  https://doi.org/10.1212/WNL.0000000000001861.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Prust ML, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, et al. Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss. Neuro-Oncology. 2018;20(2):289–91.  https://doi.org/10.1093/neuonc/nox217.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Klein M, Engelberts NH, van der Ploeg HM, Kasteleijn-Nolst Trenite DG, Aaronson NK, Taphoorn MJ, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol. 2003;54(4):514–20.  https://doi.org/10.1002/ana.10712.CrossRefPubMedGoogle Scholar
  36. 36.
    • Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S. Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumors. Nat Rev Neurol. 2017;13(1):52–64.  https://doi.org/10.1038/nrneurol.2016.185 Comprehensively reviews the mechanisms of nerual damage underlying cognitive deterioriation in patients attributable to radiation therapy, including inflammation, injury to neuronal lineages, accessory cells and their progenitors, and loss of supporting structure integrity.CrossRefPubMedGoogle Scholar
  37. 37.
    Block CK, Johnson-Greene D, Pliskin N, Boake C. Discriminating cognitive screening and cognitive testing from neuropsychological assessment: implications for professional practice. Clin Neuropsychol. 2017;31(3):487–500.  https://doi.org/10.1080/13854046.2016.1267803.CrossRefPubMedGoogle Scholar
  38. 38.
    Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro-Oncology. 2003;5(2):89–95.  https://doi.org/10.1215/S1522-8517-02-00026-1.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Baum KT, Powell SK, Jacobson LA, Gragert MN, Janzen LA, Paltin I, et al. Implementing guidelines: proposed definitions of neuropsychology services in pediatric oncology. Pediatr Blood Cancer. 2017;64(8).  https://doi.org/10.1002/pbc.26446.CrossRefGoogle Scholar
  40. 40.
    Bookheimer S. Pre-surgical language mapping with functional magnetic resonance imaging. Neuropsychol Rev. 2007;17(2):145–55.  https://doi.org/10.1007/s11065-007-9026-x.CrossRefPubMedGoogle Scholar
  41. 41.
    Gehring KSA, Etzel C, Lang F, Wefel J. Prediction of memory outcomes after resection of high-grade glioma (Abstract). Neuro-Oncology. 2011;13:iii73.Google Scholar
  42. 42.
    Gehring KSA, Etzel C, Lang F, Wefel J. Prediction of language outcomes after resection of high-grade glioma (Abstract). Neuro-Oncology. 2011;13:iii75.Google Scholar
  43. 43.
    Helmstaedter C, Witt JA. How neuropsychology can improve the care of individual patients with epilepsy. Looking back and into the future. Seizure. 2017;44:113–20.  https://doi.org/10.1016/j.seizure.2016.09.010.CrossRefPubMedGoogle Scholar
  44. 44.
    •• Kelm A, Sollmann N, Ille S, Meyer B, Ringel F, Krieg SM. Resection of gliomas with and without neuropsychological support during awake craniotomy-effects on surgery and clinical outcome. Front Oncol. 2017;7:176.  https://doi.org/10.3389/fonc.2017.00176 Demonstrates the benefit of incorporating neuropsychology services during awake craniotomy—namely that greater extent of resection and reduced surgical time are achieved.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Rostomily RC, Berger MS, Ojemann GA, Lettich E. Postoperative deficits and functional recovery following removal of tumors involving the dominant hemisphere supplementary motor area. J Neurosurg. 1991;75(1):62–8.  https://doi.org/10.3171/jns.1991.75.1.0062.CrossRefPubMedGoogle Scholar
  46. 46.
    Johnson DR, Sawyer AM, Meyers CA, O’Neill BP, Wefel JS. Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro-Oncology. 2012;14(6):808–16.  https://doi.org/10.1093/neuonc/nos082.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    •• Noll KR, Sullaway CM, Wefel JS. Depressive symptoms and executive function in relation to survival in patients with glioblastoma. J Neuro-Oncol. 2019;142(1):183–91.  https://doi.org/10.1007/s11060-018-03081-z Demonstrates the independent and combined impact of executive functioning and depressive symptoms upon surival duration in patients with glioblastoma. Patients with increased depressive ideation or executive dysfunction appear at risk of reduced survival, while those with both exhibit the worst prognosis.CrossRefGoogle Scholar
  48. 48.
    Klein M, Heimans JJ, Aaronson NK, Postma TJ, Muller M, van der Ploeg HM, et al. Impaired cognitive functioning in low-grade glioma patients: relationship to tumor localisation, radiotherapy and the use of anticonvulsants. Ned Tijdschr Geneeskd. 2004;148(44):2175–80.PubMedGoogle Scholar
  49. 49.
    Henriksson R, Asklund T, Poulsen HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neuro-Oncol. 2011;104(3):639–46.  https://doi.org/10.1007/s11060-011-0565-x.CrossRefGoogle Scholar
  50. 50.
    Mandonnet E, De Witt Hamer P, Poisson I, Whittle I, Bernat AL, Bresson D, et al. Initial experience using awake surgery for glioma: oncological, functional, and employment outcomes in a consecutive series of 25 cases. Neurosurgery. 2015;76(4):382–9; discussion 9.  https://doi.org/10.1227/NEU.0000000000000644.CrossRefPubMedGoogle Scholar
  51. 51.
    Lundqvist A. Neuropsychological aspects of driving characteristics. Brain Inj. 2001;15(11):981–94.  https://doi.org/10.1080/02699050110065637.CrossRefPubMedGoogle Scholar
  52. 52.
    Perry A, Schmidt RE. Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol. 2006;111(3):197–212.  https://doi.org/10.1007/s00401-005-0023-y.CrossRefPubMedGoogle Scholar
  53. 53.
    Dietrich J, Klein JP. Imaging of cancer therapy-induced central nervous system toxicity. Neurol Clin. 2014;32(1):147–57.  https://doi.org/10.1016/j.ncl.2013.07.004.CrossRefPubMedGoogle Scholar
  54. 54.
    Lai R, Abrey LE, Rosenblum MK, DeAngelis LM. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology. 2004;62(3):451–6.CrossRefGoogle Scholar
  55. 55.
    Tallet AV, Azria D, Barlesi F, Spano JP, Carpentier AF, Goncalves A, et al. Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol. 2012;7:77.  https://doi.org/10.1186/1748-717X-7-77.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol. 1994;12(3):627–42.  https://doi.org/10.1200/JCO.1994.12.3.627.CrossRefPubMedGoogle Scholar
  57. 57.
    DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39(6):789–96.CrossRefGoogle Scholar
  58. 58.
    Acquaye AA, Vera-Bolanos E, Armstrong TS, Gilbert MR, Lin L. Mood disturbance in glioma patients. J Neuro-Oncol. 2013;113(3):505–12.  https://doi.org/10.1007/s11060-013-1143-1.CrossRefGoogle Scholar
  59. 59.
    Rooney AG, McNamara S, Mackinnon M, Fraser M, Rampling R, Carson A, et al. Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma. J Clin Oncol. 2011;29(32):4307–12.  https://doi.org/10.1200/JCO.2011.34.8466.CrossRefPubMedGoogle Scholar
  60. 60.
    Litofsky NS, Farace E, Anderson F Jr, Meyers CA, Huang W, Laws ER Jr, et al. Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery. 2004;54(2):358–66 discussion 66–7.CrossRefGoogle Scholar
  61. 61.
    Rooney AG, McNamara S, Mackinnon M, Fraser M, Rampling R, Carson A, et al. Screening for major depressive disorder in adults with cerebral glioma: an initial validation of 3 self-report instruments. Neuro-Oncology. 2013;15(1):122–9.  https://doi.org/10.1093/neuonc/nos282.CrossRefPubMedGoogle Scholar
  62. 62.
    Litofsky NS, Resnick AG. The relationships between depression and brain tumors. J Neuro-Oncol. 2009;94(2):153–61.  https://doi.org/10.1007/s11060-009-9825-4.CrossRefGoogle Scholar
  63. 63.
    Johnson DR, Wefel JS. Relationship between cognitive function and prognosis in glioblastoma. CNS Oncol. 2013;2(2):195–201.  https://doi.org/10.2217/cns.13.5.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Gehring K, Aaronson NK, Taphoorn MJ, Sitskoorn MM. Interventions for cognitive deficits in patients with a brain tumor: an update. Expert Rev Anticancer Ther. 2010;10(11):1779–95.  https://doi.org/10.1586/era.10.163.CrossRefPubMedGoogle Scholar
  65. 65.
    Ferguson RJ, Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology. 2007;16(8):772–7.  https://doi.org/10.1002/pon.1133.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Gorske T. Therapeutic neuropsychological assessment: a humanistic model and case example. J Humanist Psychol. 2008;48(3):320–39.CrossRefGoogle Scholar
  67. 67.
    Postal K, Armstrong K. Feedback That Sticks: The Art of effectively communicating neuropsychological assessment results. New York: Oxford University Press; 2013.Google Scholar
  68. 68.
    Bergo E, Lombardi G, Pambuku A, Della Puppa A, Bellu L, et al. Cognitive rehabilitation in patients with gliomas and other brain tumors: state of the art. Biomed Res Int. 2016;2016:11.  https://doi.org/10.1155/2016/3041824.CrossRefGoogle Scholar
  69. 69.
    Gehring K, Sitskoorn MM, Gundy CM, Sikkes SA, Klein M, Postma TJ, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(22):3712–22.  https://doi.org/10.1200/JCO.2008.20.5765.CrossRefGoogle Scholar
  70. 70.
    Gehring K, Patwardhan SY, Collins R, Groves MD, Etzel CJ, Meyers CA, et al. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neuro-Oncol. 2011;107(1):165–74.  https://doi.org/10.1007/s11060-011-0723-1.CrossRefGoogle Scholar
  71. 71.
    Rapp SR, Case LD, Peiffer A, Naughton MM, Chan MD, Stieber VW, et al. Donepezil for irradiated brain tumor survivors: a phase iii randomized placebo-controlled clinical trial. J Clin Oncol. 2015;33(15):1653–9.  https://doi.org/10.1200/JCO.2014.58.4508.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology. 2013;15(10):1429–37.  https://doi.org/10.1093/neuonc/not114.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Boele FW, Douw L, de Groot M, van Thuijl HF, Cleijne W, Heimans JJ, et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro-Oncology. 2013;15(10):1420–8.  https://doi.org/10.1093/neuonc/not102.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Day J, Zienius K, Gehring K, Grosshans D, Taphoorn M, Grant R, et al. Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. Cochrane Database Syst Rev. 2014;(12):Cd011335.  https://doi.org/10.1002/14651858.CD011335.pub2.
  75. 75.
    • Noll KR, Bradshaw ME, Weinberg JS, Wefel JS. Neurocognitive functioning is associated with functional independence in newly diagnosed patients with temporal lobe glioma. Neurooncol Pract. 2018;5(3):184–93.  https://doi.org/10.1093/nop/npx028 Results show that neurocognitive impairment as identified on neuropsychological testing is related to difficulties in various functional capacities, including basic and instrumental daily tasks.CrossRefPubMedGoogle Scholar
  76. 76.
    •• Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401–9.  https://doi.org/10.1001/jama.2016.9839Practice-changing research showing differential impact of whole-brain radiation versus radiosurgery upon neurocognitive functioning in patients with brain metastases.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomized controlled trial. Lancet Oncol. 2009;10(11):1037–44.  https://doi.org/10.1016/S1470-2045(09)70263-3.CrossRefPubMedGoogle Scholar
  78. 78.
    Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(34):3810–6.  https://doi.org/10.1200/jco.2014.57.2909.CrossRefGoogle Scholar
  79. 79.
    •• Wefel JS, Noll KR, Rao G, Cahill DP. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro-Oncology. 2016;18(12):1656–63.  https://doi.org/10.1093/neuonc/now165 First demonstration of the distinct neurocognitive phenotypes associated with variation in the IDH1 gene in patients with malignant glioma. Results indicate that patients with IDH1-wild-type tumors present with more severe impairment due to greater lesion momentum.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Ahles TA, Saykin AJ, Noll WW, Furstenberg CT, Guerin S, Cole B, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12(6):612–9.  https://doi.org/10.1002/pon.742.CrossRefPubMedGoogle Scholar
  81. 81.
    Correa DD, Satagopan J, Baser RE, Cheung K, Richards E, Lin M, et al. APOE polymorphisms and cognitive functions in patients with brain tumors. Neurology. 2014;83(4):320–7.  https://doi.org/10.1212/WNL.0000000000000617.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    • Correa DD, Satagopan J, Cheung K, Arora AK, Kryza-Lacombe M, Xu Y, et al. COMT, BDNF, and DTNBP1 polymorphisms and cognitive functions in patients with brain tumors. Neuro-Oncology. 2016;18(10):1425–33.  https://doi.org/10.1093/neuonc/now057 Large cohort study of associations between various patient genetic polymorphisms and neurocognition in patients with brain tumors. Various polymorphisms in genes associated with executive and memory functions appear to modulate cognitive outcome in patients with brain tumors.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Liu Y, Zhou R, Sulman EP, Scheurer ME, Boehling N, Armstrong GN, et al. Genetic modulation of neurocognitive function in glioma patients. Clin Cancer Res. 2015;21(14):3340–6.  https://doi.org/10.1158/1078-0432.CCR-15-0168.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Correa DD, Kryza-Lacombe M, Zhou X, Baser RE, Beattie BJ, Beiene Z, et al. A pilot study of neuropsychological functions, APOE and amyloid imaging in patients with gliomas. J Neuro-Oncol. 2018;136(3):613–22.  https://doi.org/10.1007/s11060-017-2692-5.CrossRefGoogle Scholar
  85. 85.
    Bauer RM, Iverson GL, Cernich AN, Binder LM, Ruff RM, Naugle RI. Computerized neuropsychological assessment devices: joint position paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology. Clin Neuropsychol. 2012;26(2):177–96.  https://doi.org/10.1080/13854046.2012.663001.CrossRefPubMedGoogle Scholar
  86. 86.
    Snyder PJ, Jackson CE, Petersen RC, Khachaturian AS, Kaye J, Albert MS, et al. Assessment of cognition in mild cognitive impairment: a comparative study. Alzheimers Dement. 2011;7(3):338–55.  https://doi.org/10.1016/j.jalz.2011.03.009.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Farnsworth JL 2nd, Dargo L, Ragan BG, Kang M. Reliability of computerized neurocognitive tests for concussion assessment: a meta-analysis. J Athl Train. 2017;52(9):826–33.  https://doi.org/10.4085/1062-6050-52.6.03.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Cerhan JH, Caine C, Anderson SK, Johnson DR, Lachance DH, Yan E, et al. Preliminary exploration of a computerized cognitive battery and comparison with traditional testing in patients with high-grade glioma. Neuro-Oncol Pract. 2019;6(1):71–7.  https://doi.org/10.1093/nop/npy013.CrossRefGoogle Scholar
  89. 89.
    Feenstra HE, Vermeulen IE, Murre JM, Schagen SB. Online cognition: factors facilitating reliable online neuropsychological test results. Clin Neuropsychol. 2017;31(1):59–84.  https://doi.org/10.1080/13854046.2016.1190405.CrossRefPubMedGoogle Scholar
  90. 90.
    • Feenstra HE, Vermeulen IE, Murre JM, Schagen SB. Online self-administered cognitive testing using the Amsterdam Cognition Scan: establishing psychometric properties and normative data. J Med Internet Res. 2018;20(5):e192.  https://doi.org/10.2196/jmir.9298Description of an emerging online computerized cognitive testing platform with potential for use in cancer populations. Initial psychometric properties are described.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Feenstra HEM, Murre JMJ, Vermeulen IE, Kieffer JM, Schagen SB. Reliability and validity of a self-administered tool for online neuropsychological testing: The Amsterdam Cognition Scan. J Clin Exp Neuropsychol. 2018;40(3):253–73.  https://doi.org/10.1080/13803395.2017.1339017.CrossRefPubMedGoogle Scholar
  92. 92.
    Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonize studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–8.  https://doi.org/10.1016/S1470-2045(10)70294-1.CrossRefPubMedGoogle Scholar
  93. 93.
    Correa DD, Maron L, Harder H, Klein M, Armstrong CL, Calabrese P, et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol. 2007;18(7):1145–51.  https://doi.org/10.1093/annonc/mdl464.CrossRefPubMedGoogle Scholar
  94. 94.
    • Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. Neuro-Oncology. 2016;18(Suppl 2):ii13–20.  https://doi.org/10.1093/neuonc/nov291 This review critically describes various clinical outcome assessment measures used in malignant glioma clinical trials through results of a survey conducted by the National Brain Tumor Society. Areas of need for future development are highlighted.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology. 2011;13(3):353–61.  https://doi.org/10.1093/neuonc/noq203.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12(6):583–93.  https://doi.org/10.1016/S1470-2045(11)70057-2.CrossRefPubMedGoogle Scholar
  97. 97.
    Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, et al. Challenges relating to solid tumor brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013;14(10):e407–16.  https://doi.org/10.1016/S1470-2045(13)70308-5.CrossRefPubMedGoogle Scholar
  98. 98.
    NCCN. NCCN Clinical Practice Guidelines in Oncology - Survivorship. 2019. https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf. Accessed 4/8/2019 2019.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Kyle R. Noll
    • 1
  • Mariana E. Bradshaw
    • 1
  • Michael W. Parsons
    • 2
  • Erica L. Dawson
    • 3
  • Jennie Rexer
    • 1
  • Jeffrey S. Wefel
    • 1
    • 4
    Email author
  1. 1.Section of Neuropsychology, Department of Neuro-OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Neuro-Oncology, Psychology Assessment CenterMassachusetts General HospitalBostonUSA
  3. 3.Department of Psychiatry and Behavioral HealthThe Ohio State UniversityColumbusUSA
  4. 4.Department of Radiation OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations